ArticleAdvances in experimental medicine and biology2026
Immune System Involvement and Therapeutic Targets in Alzheimer's Disease: Insights from Transcriptomic Data Analysis.
Article in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative condition defined by the accumulation of amyloid-beta peptides forming neuritic plaques and neurofibrillary tangles. It is the most prevalent type of dementia, with symptoms presenting long after the onset of neuropathological alterations, complicating early diagnosis. AD likely results from a combination of age-related brain changes and various genetic, environmental, and lifestyle factors. Integrating computational neuroscience with integrative medicine offers a promising holistic approach to understanding such complicated disorders. This study utilizes bioinformatic strategies to analyze transcriptomic data from AD patients and healthy individuals, in order to discover immune-related gene expression variations and pathways implicated in AD. The key DEGs identified in this analysis are HLA-DRB4, CD79A, and FCGR3B, which play important roles in immunological activities such as antigen processing and presentation, immunoglobulin synthesis, and cAMP-dependent kinase signaling. Pathway enrichment analysis further revealed immune system involvement, including important pathways associated with immune control and signaling. These findings emphasize the crucial role of immune dysregulation in AD pathophysiology and the potential of bioinformatics in uncovering novel biomarkers and therapeutic targets, thereby enhancing our understanding of AD's molecular mechanisms and contributing to holistic health strategies.
Indexed as
Identifiers
41273582What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.